Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055014 | 0.84 | WNT3A (0.54) | MAPTMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL19631286 | 0.84 | HDAC6 (0.62) | — | |
| SCHEMBL29647714 | 0.84 | HDAC6 (0.62) | — | |
| SCHEMBL509566 | 0.82 | EGFR (0.64) | MAPTMEN1KMT2APOLBKDM4E | |
| SCHEMBL10055013 | 0.80 | WNT3A (0.48) | MAPTMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL31098952 | 0.79 | EGFR (0.57) | MAPTMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL6477749 | 0.79 | EGFR (0.57) | MAPTMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL6889611 | 0.79 | KDM4E (0.58) | MAPTCA1CA2MAPK8MEN1 | |
| Methane SCHEMBL9378754 | 0.78 | EGFR (0.55) | MAPTMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL19617468 | 0.78 | HDAC6 (0.72) | CA1CA2DRD2TBXA2RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346563-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | UNIV TAIPEI MEDICAL (TW) | 2025-11-13 | — | — | US | disclosed |
| US-11427544-B2 | Histone deacetylase 6 inhibitors and use thereof | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-08-30 | — | — | US | disclosed |
| US-20220251043-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-08-11 | — | — | US | disclosed |
| EP-3458444-B1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | UNIV TAIPEI MEDICAL (TW) | 2022-06-22 | — | — | EP | disclosed |
| EP-3458444-B1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | UNIV TAIPEI MEDICAL (TW) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021013163-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | TAIPEI MEDICAL UNIVERSITY (CN) | 2021-01-28 | — | — | WO | disclosed |
| US-20190284141-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284141-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2017200966-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284141-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | HDAC1, HDAC11, HDAC7 | MAPT 2320/4885CA1 1148/4885CA2 2033/4885 |
| US-20250346563-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | HDAC1, HDAC3, HDAC5 | MAPT 2336/4885CA1 479/4885CA2 719/4885 |
| US-20220251043-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | HDAC1, HDAC3, HDAC2 | MAPT 2296/4885CA1 418/4885CA2 741/4885 |
| US-11427544-B2 | Histone deacetylase 6 inhibitors and use thereof | HDAC1, HDAC11, HDAC7 | MAPT 2320/4885CA1 1148/4885CA2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.